Myomo, Inc. (MYO)

Over the past six months, Myomo, Inc.'s stock has experienced significant volatility and a notable decline. Key events impacting the stock include Q1, Q2 and Q3 2025 earnings reports, an insider purchase, the CMS reclassification of the MyoPro, and stock price movement. The CMS reclassification was a major positive catalyst, allowing for lump-sum payments upon delivery and improving reimbursement and access for Medicare Part B patients. The stock price gained 5.86% on November 26, 2025, but has been in a wide and falling trend in the short term.

While there isn't explicit information detailing inherent demand seasonality for Myomo, Inc.'s products and services, there are indications of seasonal considerations in the company's operational and marketing strategies. Marketing spending might be higher in Q3 than Q4 because the firm tends to reduce advertising when rates spike in October and early November due to the election and holiday season. The underlying need for MyoPro devices for individuals with neuromuscular impairments is likely consistent throughout the year, with the CMS reclassification expected to accelerate overall growth.

Myomo, Inc. is a medical robotics company specializing in wearable robotic devices that restore mobility for individuals with neuromuscular impairments. The company's primary product is the MyoPro, a custom-fabricated, non-invasive, powered arm brace that senses faint muscle signals to enable and improve functional activities for individuals with conditions such as stroke, spinal cord injury, traumatic brain injury, ALS, or MS.

Myomo, Inc. is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. The company has a global presence, delivering MyoPro devices in the U.S. and Canada. In Europe, its operations are managed from Germany, and the company has distribution partners. Myomo also has channel partners in Australia and is actively pursuing expansion into international markets, including a joint venture in China, which is progressing towards NMPA approval with an anticipated launch by the end of 2025.

Myomo, Inc. maintains a strong brand reputation within the medical robotics and assistive technology sector, primarily due to its innovative MyoPro device. The MyoPro is recognized as the only FDA-registered, commercially available device proven safe and effective for certain paralyzed individuals to restore arm and hand functions. The CMS reclassification of the MyoPro into the brace benefit category positively impacted Myomo's reputation and market standing, validating the device's medical necessity and expanding access to a larger patient population.

Myomo, Inc.'s ownership structure includes institutional, insider, and retail investors. Approximately 10.44% to 23.65% of the company's stock is held by institutional investors, 17.05% by insiders, and a significant portion (53.61% to 59.30%) by public companies and individual investors. Major institutional owners include Rosalind Advisors, Inc., BlackRock, Inc., and Vanguard Group Inc. Notable individual owners and insiders include Paul R. Gudonis, Steve Sanghi, and Gil Aharon.